A Retrospective Study of Onyx Complications in the Treatment of Arteriovenous Malformations (AVM)

Simple item page
dc.contributor.otherWhite, Jonathanen
dc.creatorSharp, Stevenen
dc.date.accessioned2016-06-20T15:52:13Z
dc.date.available2016-06-20T15:52:13Z
dc.date.issued2016-01-19
dc.descriptionThe 54th Annual Medical Student Research Forum at UT Southwestern Medical Center (Monday, January 19, 2016, 2-5 p.m., D1.700)en
dc.description.abstractINTRODUCTION: The treatment of arteriovenous malformation (AVM) with Onyx has been shown to be an effective treatment modality but outcomes and complications rates reported have been inconsistent. A meta-analysis of 103 studies with 1232 patients receiving Onyx found a complication rate of 6.8% (Elsenousi et al.) The true complication and risk of Onyx needs to be evaluated further. METHODS: We performed a 1 O year retrospective study at University of Texas Southwestern involving the treatment of AVMs with onyx as a primary or adjunct treatment. Excluded were patients that received onyx and another embolization material treatment. Complications were analyzed after embolization but before microsurgery or radiosurgery. RESULTS: Eighty-seven AVM patients received embolization and of those there were 37 patients who received onyx only or as an adjunct treatment to microsurgery or radiosurgery. The treatment plans are 7 AVM patients with onyx only, 14 AVM patients with pre-embolization for radiosurgery, 16 AVM patients with pre-embolization for microsurgery (fig. 1 ). One patient died shortly after embolization due to cerebellar hemorrhage that was present on admission and will be excluded from analysis below. There are no complications in 28/36 patients (80%), vascular complications with ciinical symptoms in 3/35 patients (8.3%), permanent neurologic deficits in 4 patients and temporary neurologic complaint in one patient (table 1 ). In the 36 patients, there were 57 embolization sessions with a permanent neurologic complication rate of 7% (4/57). CONCLUSION: The permanent complication rate of onyx is 7% in our study, which is consistent with the body of literature. Onyx is an effective treatment modality and should be considered in the treatment of AVMs. Prospective studies are needed to elucidate the complications and management of AVMs with Onyx. REFERENCES: Elsenousi, A., Aletich, V. A., & Alaraj, A. (2014). Neurological outcomes and cure rates of embolization of brain arteriovenous malformations with n·butyl cyanoacrylate or Onyx: a meta-analysis. Journal of neurointerventional surgery, neurintsurg-2014.en
dc.description.sponsorshipSouthwestern Medical Foundationen
dc.identifier.citationSharp, S., & White, J. (2016, January 19). A retrospective study of Onyx complications in the treatment of arteriovenous malformations (AVM). Poster presented at the 54th Annual Medical Student Research Forum, Dallas, TX. Retrieved from https://hdl.handle.net/2152.5/3287en
dc.identifier.urihttps://hdl.handle.net/2152.5/3287
dc.language.isoenen
dc.relation.ispartofseries54th Annual Medical Student Research Forumen
dc.subjectClinical Research and Case Reportsen
dc.subject.meshDimethyl Sulfoxideen
dc.subject.meshEmbolization, Therapeuticen
dc.subject.meshEnbucrilateen
dc.subject.meshIntracranial Arteriovenous Malformationsen
dc.subject.meshPolyvinylsen
dc.subject.meshRetrospective Studiesen
dc.titleA Retrospective Study of Onyx Complications in the Treatment of Arteriovenous Malformations (AVM)en
dc.typePresentationen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Sharp_FinalPoster_MSRF2016.pdf
Size:
2.04 MB
Format:
Adobe Portable Document Format
Description:
PDF--public access
Download

Collections

Annual Medical Student Research Forum